Discovery of selective irreversible inhibitors for Bruton's tyrosine kinase. - Wikidata - wikimedia - TriplyDB

Discovery of selective irreversible inhibitors for Bruton's tyrosine kinase.

Discovery of selective irreversible inhibitors for Bruton's tyrosine kinase.

http://www.wikidata.org/entity/Q34001339

about

Chronic active B-cell-receptor signalling in diffuse large B-cell lymphoma The Bruton tyrosine kinase inhibitor PCI-32765 blocks B-cell activation and is efficacious in models of autoimmune disease and B-cell malignancy Delineation of Polypharmacology across the Human Structural Kinome Using a Functional Site Interaction Fingerprint Approach Chronic Lymphocytic Leukemia: Exploiting Vulnerabilities with Targeted Agents BCR Signaling Inhibitors: an Overview of Toxicities Associated with Ibrutinib and Idelalisib in Patients with Chronic Lymphocytic Leukemia Ten things you should know about protein kinases: IUPHAR Review 14 Ibrutinib (PCI-32765) in chronic lymphocytic leukemia CTA095, a novel Etk and Src dual inhibitor, induces apoptosis in prostate cancer cells and overcomes resistance to Src inhibitors Structures of human Bruton's tyrosine kinase in active and inactive conformations suggest a mechanism of activation for TEC family kinases X-ray crystal structure of bone marrow kinase in the x chromosome: a Tec family kinase Discovery of Novel Irreversible Inhibitors of Interleukin (IL)-2-inducible Tyrosine Kinase (Itk) by Targeting Cysteine 442 in the ATP Pocket Targets for Ibrutinib Beyond B Cell Malignancies Characterization of a c-Rel Inhibitor That Mediates Anticancer Properties in Hematologic Malignancies by Blocking NF-κB-Controlled Oxidative Stress Responses Covalent Modifiers: A Chemical Perspective on the Reactivity of α,β-Unsaturated Carbonyls with Thiols via Hetero-Michael Addition Reactions Divergent modulation of Src-family kinase regulatory interactions with ATP-competitive inhibitors.Targeting Non-Catalytic Cysteine Residues Through Structure-Guided Drug Discovery Real-world results of ibrutinib in patients with relapsed or refractory chronic lymphocytic leukemia: data from 95 consecutive patients treated in a compassionate use program. A study from the Swedish Chronic Lymphocytic Leukemia Group.Ibrutinib inhibits BCR and NF-κB signaling and reduces tumor proliferation in tissue-resident cells of patients with CLL Future therapeutic targets in rheumatoid arthritis?Oncogenic activation of NF-kappaB.Determining Cysteines Available for Covalent Inhibition Across the Human Kinome.The Bruton tyrosine kinase inhibitor PCI-32765 thwarts chronic lymphocytic leukemia cell survival and tissue homing in vitro and in vivo.Bruton's tyrosine kinase (BTK) inhibitors in clinical trials.BTK inhibitors in chronic lymphocytic leukemia: a glimpse to the future.A structure-guided approach to creating covalent FGFR inhibitors A road map to evaluate the proteome-wide selectivity of covalent kinase inhibitors.Evolution of ibrutinib resistance in chronic lymphocytic leukemia (CLL)Ibrutinib-induced lymphocytosis in patients with chronic lymphocytic leukemia: correlative analyses from a phase II study.Kinase pathway dependence in primary human leukemias determined by rapid inhibitor screening.Design and pharmacological characterization of VUF14480, a covalent partial agonist that interacts with cysteine 98(3.36) of the human histamine H₄ receptor.Selective antitumor activity of ibrutinib in EGFR-mutant non-small cell lung cancer cells B-cell receptor signaling as a driver of lymphoma development and evolution.Inhibitors of BTK and ITK: state of the new drugs for cancer, autoimmunity and inflammatory diseases.Targeting interleukin-2-inducible T-cell kinase (ITK) and resting lymphocyte kinase (RLK) using a novel covalent inhibitor PRN694.Bruton's TK inhibitors: structural insights and evolution of clinical candidates.Novel and emerging targeted-based cancer therapy agents and methods.Modeling pharmacological inhibition of mast cell degranulation as a therapy for insulinoma.The Bruton tyrosine kinase inhibitor ibrutinib with chemoimmunotherapy in patients with chronic lymphocytic leukemia.A critical appraisal of ibrutinib in the treatment of mantle cell lymphoma and chronic lymphocytic leukemia Pharmacological and Protein Profiling Suggests Venetoclax (ABT-199) as Optimal Partner with Ibrutinib in Chronic Lymphocytic Leukemia

P2860

Q24613755-0562B103-4B52-42C6-9DD4-A2838A0CB62C Q24633214-E9479929-7E9D-43D5-B40F-0B4223E06255 Q24672143-6F82ED6A-0A25-4842-B654-55BBCFB5DE87 Q26764833-90FDA252-FB6F-4439-A969-AA16C7EF1077 Q26765624-33A7BA0C-C5CA-4EFA-8869-7653B4639CEA Q26849417-E1A31BED-3D8C-47EC-88CC-E591C26D8DC1 Q26852328-A2A15269-B12E-47FE-B0EA-BBF843957FA9 Q27309998-857A4997-D2B7-476F-9B31-E5345D50815F Q27658863-09C0BF51-88CB-4534-B466-B2545B96A5E0 Q27672770-924FB4BC-E074-4BFE-8ACD-B85ABA7B46CD Q27679513-DDE2D754-46A5-4240-B786-BB28585C8E69 Q28087772-84506837-4D76-424F-9905-E83A19DC6B12 Q28271836-F77DD385-76F5-499B-B2CE-301828E55323 Q29248430-C39CFB6D-0FFC-4738-8A1D-5BA74CD41178 Q30009417-709CA8BA-350F-4AA3-9C26-9F106F8255B1 Q30390894-31BC7D23-02AD-428F-A65F-5DA578E0656C Q31097476-39236C2F-A07D-4169-BD6E-4CDDE0E25ED7 Q33714712-BC305F16-459D-4546-BC3F-B5DCC77186A3 Q33841419-258D303B-346E-4A64-9054-DAC40092CD3C Q33849388-1457235A-D71C-41C2-8436-CC0A72EA0B23 Q33859476-9BA13CCC-2A81-4B46-9947-16E4BD82DCF6 Q34029869-5C7F0066-37E6-44BE-AF17-B0516842A4A7 Q34039406-E8F498EE-FB40-4F0E-8F7D-369102B6BAA9 Q34041311-9C680921-4700-4846-9435-35396D306B1A Q34061522-9E0D911D-1B7A-4ADC-8D7E-D9B40351B9EE Q34067085-40FD385D-F4F9-4941-A315-DCAE49704C03 Q34280885-358CDBC8-B576-4706-97D0-408197334D88 Q34289493-6AE69754-A7B4-4A0B-AAF4-169DF6A991FC Q34307423-C9061487-7A08-4DF5-8F77-A0EAB6B4A035 Q34324177-1A7519EA-97D4-47C6-A392-DCBB2FEF1A68 Q34354339-BC1C068C-BB04-48FC-8786-C4A79A2E6A81 Q34398579-C149DE8D-32DF-4560-B1B8-16721A321785 Q34722000-8F67CA1A-843C-4ADC-8BB4-C23C7C9B7A9C Q35172875-07CD7C3B-60D1-44F6-8109-0155755E97C3 Q35181271-13FF0B8E-831D-4489-A892-44E1A014EAEC Q35558057-6C2E72F9-8CB8-46A9-ADC2-8F8701143245 Q35581292-AE4B25D9-F0AA-4C54-9EAF-8EADD5C0D1F0 Q35583403-67F2F6B6-8AA8-4BFF-AE37-2329889BB7E4 Q35794593-FAE3D1A2-56CD-47E3-BDC2-1DD0DEF4CB24 Q35958056-2965A109-868B-4DA7-977E-E77EC4ED3966

P2860

Discovery of selective irreversible inhibitors for Bruton's tyrosine kinase.

http://www.wikidata.org/entity/Q34001339

description

2007 nî lūn-bûn

@nan

2007 թուականի Յունուարին հրատարակուած գիտական յօդուած

@hyw

2007 թվականի հունվարին հրատարակված գիտական հոդված

@hy

2007年の論文

@ja

2007年論文

@yue

2007年論文

@zh-hant

2007年論文

@zh-hk

2007年論文

@zh-mo

2007年論文

@zh-tw

2007年论文

@wuu

name

Discovery of selective irreversible inhibitors for Bruton's tyrosine kinase.

@ast

Discovery of selective irreversible inhibitors for Bruton's tyrosine kinase.

@en

Discovery of selective irreversible inhibitors for Bruton's tyrosine kinase.

@nl

type

label

Discovery of selective irreversible inhibitors for Bruton's tyrosine kinase.

@ast

Discovery of selective irreversible inhibitors for Bruton's tyrosine kinase.

@en

Discovery of selective irreversible inhibitors for Bruton's tyrosine kinase.

@nl

prefLabel

Discovery of selective irreversible inhibitors for Bruton's tyrosine kinase.

@ast

Discovery of selective irreversible inhibitors for Bruton's tyrosine kinase.

@en

Discovery of selective irreversible inhibitors for Bruton's tyrosine kinase.

@nl

P1433

Q34001339-0F3F1011-D69B-4865-B53E-6E37727471BE

P1476

Q34001339-92461F76-27AE-475E-B257-FFF7DDEF1750

P2093

Q34001339-0880A2A6-90D9-4C4A-B25C-F7139AF8143A

Q34001339-31FC3535-071D-423D-9FCF-6E1858E7EEF1

Q34001339-37252D77-EB66-460E-B04C-AE5B1AAFF1D7

Q34001339-39ACC2C6-60F3-49D6-B129-9A9A64B88ED1

Q34001339-50670F83-DDC5-4B8E-B3BB-7BEC6FF63974

Q34001339-523EBC67-6FE9-4EF0-BC93-69D2BCB175B7

Q34001339-730C620A-B18C-4C20-B28A-4C47FD39A1B4

Q34001339-7751B1E4-3AE0-4721-9A3B-4A8CB957A6D9

Q34001339-8A7972B6-F924-4104-9163-E8297EAC40D9

Q34001339-9F7B957F-4C02-4483-BC2B-DAF598ECE72A

P2860

Q34001339-4AD515B5-7052-445D-A1E9-FDB29724847C

P304

Q34001339-E07827BC-F1CB-4F6F-807D-D54269EB795B

P31

Q34001339-145B352C-FB20-4DE4-90C6-82BC3EDEA99A

P356

Q34001339-BF04E55F-32E5-4D87-8A3E-6423BDB2C1A6

P433

Q34001339-6DC96C77-16D5-4AD8-B146-E61B26E04E68

P478

Q34001339-C7D5D01A-8974-4EDF-A783-2D823192EC41

P577

Q34001339-882A7884-F5A9-4790-993B-57295DFE1F3C

P5875

Q34001339-723E1812-A99F-453E-8813-08E5CDE4E985

P698

Q34001339-2A211862-6CF2-447F-B447-59E49E2D0AC7

P356

P1433

P1476

Discovery of selective irreversible inhibitors for Bruton's tyrosine kinase.

@en

P2093

Brian E Schultz

http://www.w3.org/2001/XMLSchema#string

Douglas A Jeffery

http://www.w3.org/2001/XMLSchema#string

Heleen Scheerens

http://www.w3.org/2001/XMLSchema#string

James T Palmer

http://www.w3.org/2001/XMLSchema#string

Jill M Spoerke

http://www.w3.org/2001/XMLSchema#string

Keana C K Scott

http://www.w3.org/2001/XMLSchema#string

L Chuck Burrill

http://www.w3.org/2001/XMLSchema#string

Lee A Honigberg

http://www.w3.org/2001/XMLSchema#string

Michael D Sweeney

http://www.w3.org/2001/XMLSchema#string

Paul A Sprengeler

http://www.w3.org/2001/XMLSchema#string

P2860

Collagen type II-specific monoclonal antibody-induced arthritis in mice: description of the disease and the influence of age, sex, and genes

P304

58-61

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1002/CMDC.200600221

http://www.w3.org/2001/XMLSchema#string

P433

1

http://www.w3.org/2001/XMLSchema#string

P478

2

http://www.w3.org/2001/XMLSchema#string

P577

2007-01-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

6645799

http://www.w3.org/2001/XMLSchema#string

P698

17154430

http://www.w3.org/2001/XMLSchema#string